优选的突触类型的GABA-A受体配体增强神经元的存活率,并促进缺血性中风后的功能恢复
Barbara Mordyl1, Nikola Fajkis-Zajączkowska2, Katarzyna Szafrańska2,3
1Department of Pharmacobiology, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, Kraków 30-688, Poland.
Journal of medicinal chemistry
|December 13, 2024
概括
研究人员开发了新的GABA-A受体配体,以增强中风恢复的突触信号传递. 化合物4在临床前模型中改善了神经元功能和运动恢复,显示神经保护作用.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 通过GABA-A受体选择性增强突触GABA信号,有助于在缺血性中风后的功能恢复.
- 相反,强烈的GABA信号已经被证明对恢复有害.
研究的目的:
- 为了确定选择性增强突触GABA信号传递的新型药物.
- 在缺血性中风的临床前模型中评估这些药物的治疗潜力.
主要方法:
- 在三种化学类型中合成GABA-A配体,具有高亲和力 (pKi=6.44-8.32).
- 评估受体亚型偏好 (突触与异突触).
- 在细胞 (氧气-葡萄糖缺乏) 和缺血性中风的动物模型中进行评估.
主要成果:
- 选择的化合物显示出对突触GABA-A受体的偏好.
- 化合物4通过减少线粒体功能障碍,调节,降低酶3和促进神经元外生,改善了体外神经元的恢复.
- 化合物4在动物模型中增强了运动恢复和减少了心脏病发作量和酸性疾病.
结论:
- 突触GABA-A受体的选择性调节为缺血性中风提供了一个有前途的治疗策略.
- 化合物4具有显著的神经保护和功能恢复潜力.
- 针对突触GABA信号传递是中风治疗的一个有价值的方法.
相关概念视频
Antiepileptic Drugs: GABAergic Pathway Potentiators
328
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
328
Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.1K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.1K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
248
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
248
Ligand-gated Ion Channels
12.2K
Ligand-gated ion channels are transmembrane proteins with a channel for ions to pass through and a binding site for a ligand. The channel opens only when a ligand attaches to the binding site.
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that...
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that...
12.2K
Antiepileptic Drugs: Potassium Channel Activators
144
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
144
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
96
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
96


